Stemline Therapeutics, Inc.
STML
STML was delisted on the 9th of June, 2020.
74 hedge funds and large institutions have $104M invested in Stemline Therapeutics, Inc. in 2016 Q4 according to their latest regulatory filings, with 13 funds opening new positions, 30 increasing their positions, 15 reducing their positions, and 9 closing their positions.
101% more call options, than puts
Call options by funds: $690K | Put options by funds: $344K
100% more repeat investments, than reductions
Existing positions increased: 30 | Existing positions reduced: 15
95% more capital inflows, than outflows
Capital inflows: $19.9M | Capital outflows: $10.2M
44% more first-time investments, than exits
New positions opened: 13 | Existing positions closed: 9
6% more funds holding
Funds holding: 70 → 74 (+4)
4.09% more ownership
Funds ownership: 46.72% → 50.81% (+4.1%)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
SM
Sabby Management
Miami Beach,
Florida
|
+$3.14M |
| 2 |
Farallon Capital Management
San Francisco,
California
|
+$3.11M |
| 3 |
J. Goldman & Co
New York
|
+$2.42M |
| 4 |
Millennium Management
New York
|
+$1.38M |
| 5 |
Bogle Investment Management
Newton Lower Falls,
Massachusetts
|
+$1.15M |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Fidelity Investments
Boston,
Massachusetts
|
-$4.67M |
| 2 |
Franklin Resources
San Mateo,
California
|
-$2.34M |
| 3 |
Royce & Associates
New York
|
-$852K |
| 4 |
Columbus Circle Investors
|
-$580K |
| 5 |
Mackenzie Financial
Toronto Ontario,
Ontario, Canada
|
-$400K |
STML Hedge Fund Activity: Q4 2016 in Review
74 of the 4,008 institutional investors tracked by Wall St. Rank reported a position in Stemline Therapeutics, Inc. (STML) for Q4 2016, worth a combined $104M — up 7.5% from $96.9M a quarter earlier.
Buyers outnumbered sellers: 13 funds opened new STML positions and 9 closed out — a net gain of 4 holders — while 30 added to existing stakes and 15 trimmed.
The largest buyer was Sabby Management, adding an estimated $3.14M. The largest seller was Fidelity Investments, cutting an estimated $4.67M.
- 74 institutional investors held Stemline Therapeutics, Inc. (STML) as of Q4 2016, up from 70 in Q3 2016.
- Funds reported $104M of Stemline Therapeutics, Inc. stock for Q4 2016, up 7.5% quarter-over-quarter.
- 13 funds opened new Stemline Therapeutics, Inc. positions in Q4 2016 and 9 closed out, a net change of +4 holders.
- The largest Stemline Therapeutics, Inc. buyer in Q4 2016 was Sabby Management, an estimated $3.14M added.
- The largest Stemline Therapeutics, Inc. seller in Q4 2016 was Fidelity Investments, an estimated $4.67M sold.
Based on aggregated 13F filings for Q4 2016.